Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART

Franco Pandolfi, Marina Pierdominici, Marco Marziali, Maria Livia Bernardi, Guido Antonelli, Vincenzo Galati, Gianpiero D'Offizi, Fernando Aiuti

Research output: Contribution to journalArticlepeer-review


During HIV disease an increased in vitro apoptosis of peripheral blood mononuclear cells has been demonstrated. This can be reversed in vitro by interleukin (IL)-2. Recent trials with highly active antiretroviral therapy (HAART) and IL-2 in HIV-1-infected patients showed promising immunological and clinical results. Here we investigated the effects of subcutaneous low- dose IL-2 administration in combination with HAART on in vitro apoptosis and the relationship between apoptosis, CD4+ counts, and HIV replication. Twenty-two asymptomatic HIV patients were randomized for HAART (arm I) and HAART plus IL-2 (arm II). Spontaneous apoptosis was decreased in both arms after 28 weeks of therapy but the reduction was highly significant only in arm II (P = 0.05 vs P = 0.001). As the percentage of apoptosis decreased, there was a significantly higher increase of both CD4+ and CD4+ naive T cells in arm II vs arm I. HIV plasma viremia was reduced in all patients after therapy. Our data suggest that intermittent therapy with low-dose subcutaneous IL-2 in addition to HAART induces a positive immunomodulation in asymptomatic HIV-infected patients. (C) 2000 Academic Press.

Original languageEnglish
Pages (from-to)153-159
Number of pages7
JournalClinical Immunology
Issue number3
Publication statusPublished - Mar 2000


  • Apoptosis
  • CD4 T cells
  • HIV viremia
  • Interleukin-2

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine


Dive into the research topics of 'Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART'. Together they form a unique fingerprint.

Cite this